Development and Validation of a Reverse-Phase High-Performance Liquid Chromatography with Fluorescence Detection (RP-HPLC-FL) Method to Quantify Ruxolitinib in Plasma Samples-Reference-Cited by-同舟云学术

Development and Validation of a Reverse-Phase High-Performance Liquid Chromatography with Fluorescence Detection (RP-HPLC-FL) Method to Quantify Ruxolitinib in Plasma Samples

Published:2019-03-26 Issue:8 Volume:52 Page:1328-1339
ISSN:0003-2719
Container-title:Analytical Letters
language:en
Short-container-title:Analytical Letters

Author:

Charlier Bruno¹²,Marino Luigi³,Dal Piaz Fabrizio²³,Pingeon Marine³,Coglianese Albino³,Izzo Barbara⁴⁵,Serio Bianca²,Selleri Carmine²³,Filippelli Amelia²³,Izzo Viviana²³

Affiliation:

1. Postgraduate School in Hospital Pharmacy, University of Salerno, Fisciano, Salerno, Italy;

2. University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy;

3. Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy;

4. Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy;

5. CEINGE-Biotecnologie Avanzate, Naples, Italy

Publisher

Informa UK Limited

Subject

Electrochemistry,Biochemistry (medical),Clinical Biochemistry,Spectroscopy,Biochemistry,Analytical Chemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/00032719.2018.1537283

Reference26 articles.

1. Experience with ruxolitinib in the treatment of polycythaemia vera

2. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

3. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

4. Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing pharmacokinetics and drug-drug interactions of the combination therapy of myelofibrosis with ruxolitinib and lenalidomide by a new eco-friendly HPLC method for their simultaneous determination in plasma;Cancer Chemotherapy and Pharmacology;2024-09-11

2. Electrochemical Behavior of Janus Kinase Inhibitor Ruxolitinib at a Taurine-Electropolymerized Carbon Paste Electrode: Insights into Sensing Mechanisms;ACS Applied Bio Materials;2024-04-06

3. Green HPTLC - Densitometric approach for quantitation of Ruxolitinib in bulk and marketed formulation;Research Journal of Pharmacy and Technology;2023-09-30

4. Novel microwell-based spectrofluorimetric method assisted with fluorescence plate reader for determination of ruxolitinib: Optimization by response surface methodology and application to in-vitro drug release, content uniformity testing and analysis of u…;Talanta Open;2023-08

5. STABILITY INDICATING ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF RUXOLITINIB IN BULK AND PHARMACEUTICAL DOSAGE FORM USING UPLC;International Journal of Pharmacy and Pharmaceutical Sciences;2023-02-01